SCHEMBL984419

SCHEMBL984419

CS(=O)(=O)Nc1ccc(C2=NN(C(=O)CC3=CC4=CNSN4C=C3)CC2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.36
HPGD P15428 6/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 9/20 0.36
GLA P06280 6/20 0.36
GAA P10253 4/20 0.36
PKM P14618 1/20 0.36
NPC1 O15118 1/20 0.35
KMT2A Q03164 7/20 0.34
MAPT P10636 5/20 0.33
HTT P42858 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 5/20 0.33
BCL2 P10415 2/20 0.33
BECN1 Q14457 2/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
POLB P06746 2/20 0.33
LMNA P02545 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980716 0.85 ALDH1A1 (0.39) ALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL980252 0.85 PGR (0.39) ALDH1A1HPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL979414 0.85 MAOB (0.39) ALDH1A1HPGDSMN1; SMN2RAB9ANPSR1
SCHEMBL984417 0.84 L3MBTL1 (0.40) ALDH1A1HPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL17004410 0.84 ALDH1A1 (0.39) ALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL980472 0.80 MAOB (0.53) ALDH1A1HPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL981836 0.78 MAOB (0.43) ALDH1A1HPGDSMN1; SMN2RAB9AGAA
SCHEMBL979450 0.78 PGR (0.38) ALDH1A1HPGDSMN1; SMN2RAB9APKM
SCHEMBL17004385 0.78 SMN1; SMN2 (0.34) ALDH1A1HPGDSMN1; SMN2RAB9AKDM4E
SCHEMBL979927 0.77 MAOA (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885HPGD 2204/4885SMN1; SMN2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.